Trade UTHR stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
United Therapeutics Corporation (UTHR) is trading at US$497.59, up 0.91% today as of Sep 22, 16:00 EDT. The company has a market capitalisation of US$22.01B. Over the past 52 weeks, UTHR has traded between US$409.07 and US$609.35. On Syfe you can trade UTHR with $0 commission and add it to your watchlist.
| Previous close | US$493.10 |
|---|---|
| Market cap | US$22.01B |
| P/E ratio | 17.69 |
| 52-week range | US$409.07 – US$609.35 |
| Volume | 392.85K |
| Exchange | US |
Add to Watchlist
Set Price Alert
United Therapeutics Corporation
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Year: 1999
United Therapeutics Corporation (UTHR) stock is trading at US$497.59, +0.91% from the previous close of US$493.10.
The market cap for United Therapeutics Corporation (UTHR) stock is approximately US$22.01B.
The price-to-earnings ratio for United Therapeutics Corporation (UTHR) is 17.69, based on the latest reported earnings.
The 52-week high for United Therapeutics Corporation (UTHR) stock is US$609.35.
The 52-week low for United Therapeutics Corporation (UTHR) stock is US$409.07.
United Therapeutics Corporation (UTHR) does not currently pay a dividend.
Stay on top of UTHR
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
